Pearce C J, Byfield P G, Edmonds C J, Lalloz M R, Himsworth R L
Clin Endocrinol (Oxf). 1981 Jul;15(1):1-10. doi: 10.1111/j.1365-2265.1981.tb02741.x.
Serum thyroxine was consistently unmeasurable by radioimmunoassay in an elderly patient with myxoedema after successful treatment with oral thyroxine. Abnormal binding of thyroxine was suspected and shown to be due to the presence in serum of antibodies of the IgG variety. The characteristics of these antibodies with respect to their binding of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and human thyroglobulin (Tg) were systematically studied. Three preparations of Tg, and t4, T3 and rT3 were examined for their ability to compete with 125I-Tg, 125I-T4, 125I-T3 and 125I-rT3 for binding to the antibodies. For each tracer used the order of competitive efficiency was Tg greater than T4 greater than T3 greater than rT3. This provides for the first time direct evidence that iodothyronine reacting antibodies occurring in man are generated against Tg. All three iodothyronines were able to inhibit tracer binding of labelled iodothyronines completely, the order of effectiveness being T4 greater than T3 greater than rT3, suggesting antibodies with one type of binding site and that these were probably raised against a Tg sequence incorporating T4, although there was some evidence for the existence of a minor subpopulation of antibodies with higher specificity for T3. Complete displacement of labelled Tg by cold iodothyronines, however, was not possible. The experimental evidence suggests two classes of Tg antibodies, 70% of which were directed towards the T4 containing region, and 30% directed against other part(s) of the Tg molecule. Despite the presence of such Tg antibodies conventional haemagglutination tests of the patient's serum for Tg antibodies were negative.
在一名黏液性水肿老年患者经口服甲状腺素成功治疗后,用放射免疫分析法始终无法检测到血清甲状腺素。怀疑存在甲状腺素结合异常,并证实是由于血清中存在IgG类抗体。系统研究了这些抗体与甲状腺素(T4)、三碘甲状腺原氨酸(T3)、反三碘甲状腺原氨酸(rT3)和人甲状腺球蛋白(Tg)结合的特性。检测了三种Tg制剂以及T4、T3和rT3与¹²⁵I-Tg、¹²⁵I-T4、¹²⁵I-T3和¹²⁵I-rT3竞争结合抗体的能力。对于每种所用的示踪剂,竞争效率顺序为Tg>T4>T3>rT3。这首次提供了直接证据,表明人类中出现的碘甲状腺原氨酸反应性抗体是针对Tg产生的。所有三种碘甲状腺原氨酸都能够完全抑制标记碘甲状腺原氨酸的示踪剂结合,有效性顺序为T4>T3>rT3,表明抗体具有一种结合位点类型,并且这些抗体可能是针对包含T4的Tg序列产生的,尽管有一些证据表明存在对T3具有更高特异性的少量抗体亚群。然而,冷碘甲状腺原氨酸无法完全取代标记的Tg。实验证据表明存在两类Tg抗体,其中70%针对含T4区域,30%针对Tg分子的其他部分。尽管存在此类Tg抗体,但患者血清针对Tg抗体的传统血凝试验呈阴性。